Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for tofacitinib (Xeljanz and generics) for treatment of adult patients with active ankylosing spondylitis (AS) who responded inadequately to biologic disease modifying anti-rheumatic drugs (DMARDs) or when those drugs are not advised.